Construction and testing of mouse-human heteromyelomas for human monoclonal antibody production

N. N H Teng, Kit Lam, F. C. Riera, H. S. Kaplan

Research output: Contribution to journalArticle

130 Citations (Scopus)

Abstract

FU-266, a mutant human myeloma cell line sensitive to hypoxanthine/aminopterin/thymidine (HAT), was transfected by protoplast fusion with DNA of the recombinant plasmid vector pSV2-neo(R), thus acquiring a dominant marker conferring resistance to the antibiotic G-418. One of the resultant neo(R) clones, E-1, was fused to irradiated (500 rads) or unirradiated cells of the HAT-sensitive, G-418-sensitive, nonproducer mouse myeloma line X63-Ag8.653. Hybrid clones were selected in G-418 plus ouabain, thus preserving their HAT sensitivity. Small numbers of human chromosomes were retained in all such hybrids, but most of them ceased secreting human myeloma IgE(λ). Selected hybrid clones were then tested as malignant fusion partners in a series of fusions with polyclonally activated human B lymphocytes and with antigen-primed human B lymphocytes, in some instances after transformation of the latter with Epstein-Barr virus. The yield of viable chimeric hybridomas has been consistently high, as has the proportion of hybridomas secreting human immunoglobulin molecules unpermuted with mouse or human myeloma heavy or light chains. Secretion by many subcloned hybridomas has been stable for over 6 months, and several antigen-specific human monoclonal antibodies have been generated. Thus these heteromyeloma cell lines appear to have significant advantages for human monoclonal antibody production.

Original languageEnglish (US)
Pages (from-to)7308-7312
Number of pages5
JournalProceedings of the National Academy of Sciences of the United States of America
Volume80
Issue number23 I
StatePublished - 1983
Externally publishedYes

Fingerprint

Antibody Formation
Monoclonal Antibodies
Aminopterin
Hypoxanthine
Hybridomas
Thymidine
Clone Cells
B-Lymphocytes
Antigens
Cell Line
Recombinant DNA
Protoplasts
Human Chromosomes
Ouabain
Human Herpesvirus 4
Immunoglobulin E
Immunoglobulins
Plasmids
Light
antibiotic G 418

ASJC Scopus subject areas

  • General
  • Genetics

Cite this

Construction and testing of mouse-human heteromyelomas for human monoclonal antibody production. / Teng, N. N H; Lam, Kit; Riera, F. C.; Kaplan, H. S.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 80, No. 23 I, 1983, p. 7308-7312.

Research output: Contribution to journalArticle

@article{a3a27f16f65e4c5fae45565c48c3f8dd,
title = "Construction and testing of mouse-human heteromyelomas for human monoclonal antibody production",
abstract = "FU-266, a mutant human myeloma cell line sensitive to hypoxanthine/aminopterin/thymidine (HAT), was transfected by protoplast fusion with DNA of the recombinant plasmid vector pSV2-neo(R), thus acquiring a dominant marker conferring resistance to the antibiotic G-418. One of the resultant neo(R) clones, E-1, was fused to irradiated (500 rads) or unirradiated cells of the HAT-sensitive, G-418-sensitive, nonproducer mouse myeloma line X63-Ag8.653. Hybrid clones were selected in G-418 plus ouabain, thus preserving their HAT sensitivity. Small numbers of human chromosomes were retained in all such hybrids, but most of them ceased secreting human myeloma IgE(λ). Selected hybrid clones were then tested as malignant fusion partners in a series of fusions with polyclonally activated human B lymphocytes and with antigen-primed human B lymphocytes, in some instances after transformation of the latter with Epstein-Barr virus. The yield of viable chimeric hybridomas has been consistently high, as has the proportion of hybridomas secreting human immunoglobulin molecules unpermuted with mouse or human myeloma heavy or light chains. Secretion by many subcloned hybridomas has been stable for over 6 months, and several antigen-specific human monoclonal antibodies have been generated. Thus these heteromyeloma cell lines appear to have significant advantages for human monoclonal antibody production.",
author = "Teng, {N. N H} and Kit Lam and Riera, {F. C.} and Kaplan, {H. S.}",
year = "1983",
language = "English (US)",
volume = "80",
pages = "7308--7312",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "23 I",

}

TY - JOUR

T1 - Construction and testing of mouse-human heteromyelomas for human monoclonal antibody production

AU - Teng, N. N H

AU - Lam, Kit

AU - Riera, F. C.

AU - Kaplan, H. S.

PY - 1983

Y1 - 1983

N2 - FU-266, a mutant human myeloma cell line sensitive to hypoxanthine/aminopterin/thymidine (HAT), was transfected by protoplast fusion with DNA of the recombinant plasmid vector pSV2-neo(R), thus acquiring a dominant marker conferring resistance to the antibiotic G-418. One of the resultant neo(R) clones, E-1, was fused to irradiated (500 rads) or unirradiated cells of the HAT-sensitive, G-418-sensitive, nonproducer mouse myeloma line X63-Ag8.653. Hybrid clones were selected in G-418 plus ouabain, thus preserving their HAT sensitivity. Small numbers of human chromosomes were retained in all such hybrids, but most of them ceased secreting human myeloma IgE(λ). Selected hybrid clones were then tested as malignant fusion partners in a series of fusions with polyclonally activated human B lymphocytes and with antigen-primed human B lymphocytes, in some instances after transformation of the latter with Epstein-Barr virus. The yield of viable chimeric hybridomas has been consistently high, as has the proportion of hybridomas secreting human immunoglobulin molecules unpermuted with mouse or human myeloma heavy or light chains. Secretion by many subcloned hybridomas has been stable for over 6 months, and several antigen-specific human monoclonal antibodies have been generated. Thus these heteromyeloma cell lines appear to have significant advantages for human monoclonal antibody production.

AB - FU-266, a mutant human myeloma cell line sensitive to hypoxanthine/aminopterin/thymidine (HAT), was transfected by protoplast fusion with DNA of the recombinant plasmid vector pSV2-neo(R), thus acquiring a dominant marker conferring resistance to the antibiotic G-418. One of the resultant neo(R) clones, E-1, was fused to irradiated (500 rads) or unirradiated cells of the HAT-sensitive, G-418-sensitive, nonproducer mouse myeloma line X63-Ag8.653. Hybrid clones were selected in G-418 plus ouabain, thus preserving their HAT sensitivity. Small numbers of human chromosomes were retained in all such hybrids, but most of them ceased secreting human myeloma IgE(λ). Selected hybrid clones were then tested as malignant fusion partners in a series of fusions with polyclonally activated human B lymphocytes and with antigen-primed human B lymphocytes, in some instances after transformation of the latter with Epstein-Barr virus. The yield of viable chimeric hybridomas has been consistently high, as has the proportion of hybridomas secreting human immunoglobulin molecules unpermuted with mouse or human myeloma heavy or light chains. Secretion by many subcloned hybridomas has been stable for over 6 months, and several antigen-specific human monoclonal antibodies have been generated. Thus these heteromyeloma cell lines appear to have significant advantages for human monoclonal antibody production.

UR - http://www.scopus.com/inward/record.url?scp=0021041087&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021041087&partnerID=8YFLogxK

M3 - Article

C2 - 6316357

AN - SCOPUS:0021041087

VL - 80

SP - 7308

EP - 7312

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 23 I

ER -